Transaction & Capital Advisory · Healthcare and Consumer Health

Capital and transaction advisory for founder-led healthcare businesses across Southeast Asia and Australia.

We advise healthcare and consumer health companies with enterprise values of US$5–75 million on capital raisings, acquisitions and divestments, and provide access to strategic and financial investors across Asia and Australia. Vietnam is our anchor market.

US$5–75m
Enterprise value
US$10–40m
Core focus
Capital · Buy-side · Sell-side
Advisory mandates
SE Asia & Australia
Markets
The firm

We are deliberately selective. We accept a limited number of mandates each year, and every engagement is partner-led from preparation through to completion.

A

Capital raising

For companies planning a capital raise or debt restructuring, from capital structure review to investor relations.

Capital advisory
B

Buy-side

For strategic and financial investors entering Vietnam, from market assessment to signed acquisition.

For international investors
C

Sell-side

For shareholders considering a sale: preparing the business first, then running a competitive process.

Sell-side advisory
Latest from UCP Intelligence

The first issue will be published in March 2027.

Services

Advisory across the transaction lifecycle.

Our services span capital advisory, buy-side, sell-side, and valuation and intelligence. Engagements typically begin with capital structuring or value creation, so that a business approaches the market only when it is ready.

A
Capital advisory
A1

Capital Structuring Review

For companies considering a capital raise that have yet to determine its quantum and form.

4–6 weeks
A3

Investor Relations Retainer

For companies that have recently closed a round and now report to institutional shareholders.

12 months
B
Buy-side advisory
B1

Market Entry Map

For foreign strategic and financial investors assessing entry into Vietnam.

4–6 weeks
B2

Retained Target Search

For investors committed to Vietnam who need targets identified, approached and secured.

9–12 months
C
Sell-side advisory
C1

Value Creation Program

For shareholders planning a sale within 18–24 months whose business is not yet transaction-ready.

12 months
C2

Sell-side M&A Mandate

For shareholders who have resolved to sell all or a controlling interest.

9–12 months
D
Valuation & intelligence
D1

Valuation & Deal Structuring

For boards and shareholders who need a defensible valuation and structure for a negotiation or decision.

3–4 weeks
D2

UCP Intelligence

Periodic sector briefs on healthcare and consumer health in Vietnam and the region.

Quarterly · complimentary
Sectors

Focused on two core sectors.

Each sub-sector has its own investor universe, valuation drivers and regulatory framework. We concentrate on two, so that every mandate is supported by genuine sector depth.

Sector 01

Healthcare delivery & distribution

  • Pharmacy retail and pharmaceutical distribution
  • Clinics
  • Diagnostic chains
  • Medical-device distribution
Sector 02

Consumer health

  • Vitamins and supplements
  • Derma-cosmetics
  • Consumer health brands and distribution
How we work

Our principles of engagement.

I

Mandates we believe can be completed

Where valuation expectations diverge from the market, or the financials are not yet ready for due diligence, we raise it early and recommend the preparatory work first.

II

No competing mandates

We do not act on directly competing mandates in the same sub-sector at the same time.

III

Interests disclosed in writing

All interests of our partners and advisers are disclosed in the engagement letter before work begins.

IV

Independent specialist advisers

Legal, tax and specialist due diligence are undertaken by independent firms and coordinated by UCP.

Vietnam
Anchor market
Origination, founder relationships and execution
Mekong & Thailand
Regional coverage
Cambodia, Laos, Thailand
Australia
Home base
Licensing, capital and Australian investors
Japan · Korea · China · Singapore
Strategic investors
Acquirers of healthcare assets in the region
For international investors

Entering Vietnam's healthcare market.

For strategic and financial investors assessing healthcare or consumer health in Vietnam. The Market Entry Map provides the basis for deciding whether to enter, and how.

01

Size and structure of the sub-sector, key participants and degree of fragmentation

02

Regulatory framework and foreign ownership limits applicable to the sub-sector

03

Precedent transactions: acquirer, structure and disclosed valuation

04

20–30 potential targets, with scale, ownership and transaction readiness

05

Recommended entry route: acquisition, joint venture, distribution partnership or greenfield

B2

Retained Target Search

Once the decision to enter Vietnam is made, the challenge is no longer information but access to the right decision-makers. We screen against agreed investment criteria, approach owners directly and manage the process through to signing.

B1

Market Entry Map

  • A 25–35 page report in English
  • Target list with company-level commentary
  • A 90-minute presentation to your leadership team
  • Report owned by the client and never resold
4–6 weeks
Start a conversation
UCP Intelligence

Perspectives on healthcare capital and transactions.

Periodic sector briefs on healthcare and consumer health, with a focus on Vietnam and Southeast Asia: market structure, transaction activity, valuation benchmarks and regulatory developments.

Access
Complimentary
Frequency
Quarterly, at the end of each quarter, from March 2027
Client information
Never used, anonymised or otherwise
Archive · The first issue will be published in March 2027.

Subscribe to UCP Intelligence

Our People

The team behind every mandate.

Angelia Le
Managing Partner

Angelia Le founded UCP after more than fifteen years in M&A, private equity and venture capital across Asia-Pacific, complemented by direct experience building and operating consumer health businesses.

She established UCP to address a specific gap: founder-led healthcare businesses in Southeast Asia that require capital before they contemplate an exit, and an adviser able to bring Asian and Australian capital to the table.

Trần Đại Thắng
Senior Advisor, Healthcare · Vietnam

Mr Thắng is Chairman of EHC Group, a Vietnamese healthcare technology company whose hospital information, electronic medical record, laboratory and imaging systems are deployed in more than 50 hospitals in Vietnam and abroad. He advises UCP on sector themes and due diligence in health technology and diagnostics.

Disclosure of interestsMr Thắng is Chairman of EHC Group. UCP will not act on any mandate involving EHC Group without prior written disclosure to all parties.
Hospital digitisationHealth-tech due diligenceDiagnostics
Thảo Ngô
MRICS, CFA
Manager, Capital Advisory & Valuation

Thảo is an investment, valuation and capital markets professional with more than nine years of experience across business valuation, investment advisory, M&A and corporate finance. A Chartered Valuation Surveyor (MRICS) and CFA charterholder, she has led valuations of more than 55 greenfield projects and 500 residential properties, as well as business and equity valuations across real estate, healthcare, pharmaceuticals, logistics and renewable energy.

Her transaction experience spans financial modelling, transaction advisory, strategic equity investments, corporate restructuring and debt financing, on transactions of up to US$52 million. In capital markets, she has structured financings, led capital raisings and investor relations programmes, and arranged loan and bond financings.

ValuationCapital raisingFinancial modellingDebt & bond financing
Contact

Speak with us.

An initial meeting of 60–90 minutes, without fee or the need for an NDA, to explore whether there is a basis to work together. All discussions are held in confidence.

Or write to angelia.le@upsiloncapitalpartners.com